Literature DB >> 6368888

Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response.

A B Sabin, A Flores Arechiga, J Fernández de Castro, P Albrecht, J L Sever, I Shekarchi.   

Abstract

In 4- and 5-month-old infants in whom the undiluted chick embryo fibroblast (CEF) Schwarz strain measles vaccine had a poor immunogenic effect, there was an increase in immunogenicity when the high sugar concentration was diminished without reference to added albumin. The human diploid cell (HDC) measles vaccine was still superior in this age group even in a lower concentration of the Ikić, Edmonston-Zagreb strain of virus. More aerosolized, HDC Ikić strain virus was required for high seroconversion rates in 4- and 5-month-old infants who had higher titers of prevaccination plaque-neutralizing (PN) antibodies. Some of these infants had a delayed immune response that was absent at six weeks but present at three months after vaccination. The data provided evidence that the PN and enzyme-linked immunosorbent assay techniques measured different antibodies that develop and persist in different ways in 4- to 5-month-old infants. The HDC lyophilized measles vaccine yielded unexpectedly high seroconversion rates after subcutaneous injection of 5,000 plaque-forming units (PFUs) in 4-, 5-, and 6-month-old infants: 69%, 89%, and 100% respectively, at 14 weeks. In 12- to 23-month-old infants there was seroconversion of 92% and 100% at six weeks after inhalation of an estimated 175 PFUs of the CEF vaccine and 375 PFUs of the HDC vaccine, respectively. Within six weeks after vaccination, the PN antibody titers were significantly higher with the CEF vaccine (geometric mean titer of 2,275) than with the HDC vaccine (geometric mean titer of 343).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368888

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

1.  Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

Authors:  C D Partidos; P Vohra; M W Steward
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

2.  Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

Authors:  F Bouche; W Ammerlaan; F Berthet; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

3.  Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously.

Authors:  Rosa María Wong-Chew; Miguel Leonardo García-León; Bogart Espinosa-Torres Torrija; Brenda Hernández-Pérez; Lino E Cardiel-Marmolejo; Judy A Beeler; Susette Audet; José Ignacio Santos-Preciado
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

4.  Evaluation of live attenuated measles vaccines prepared in human diploid cells for reimmunization.

Authors:  H Mirchamsy; A Shafyi; P Nazari; M P Ashtiani; A Sassani
Journal:  Epidemiol Infect       Date:  1988-10       Impact factor: 2.451

5.  Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control.

Authors:  A B Sabin
Journal:  Eur J Epidemiol       Date:  1991-01       Impact factor: 8.082

6.  Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.

Authors:  P Kiepiela; H M Coovadia; W E Loening; P Coward; G Botha; J Hugo; P J Becker
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

7.  A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.

Authors:  Svetomir N Markovic; Vera J Suman; Wendy K Nevala; Louis Geeraerts; Edward T Creagan; Lori A Erickson; Kendrith M Rowland; Roscoe F Morton; William L Horvath; Mark R Pittelkow
Journal:  Am J Clin Oncol       Date:  2008-12       Impact factor: 2.339

8.  Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine.

Authors:  G Giammanco; S Li Volti; I Salemi; G Giammanco Bilancia; L Mauro
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

Review 9.  An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children.

Authors:  Daisy Higginson; Evropi Theodoratou; Harish Nair; Tanvir Huda; Lina Zgaga; Suresh S Jadhav; Saad B Omer; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

Review 10.  The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update.

Authors:  Beth L Laube
Journal:  Transl Respir Med       Date:  2014-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.